Poster EAACI 2014 Kopenhagen Brussels, May 28th 2014
Clinical data obtained with gpASIT+TM in the treatment of grass pollen rhinoconjonctivitis will be presented during two sessions of the international congress organized by European Academy of Allergy and Clinical Immunology (EAACI) in Copenhagen, June 7-11, 2014.
On Sunday June 8th, Dr. M. Shamji from the Imperial College, London, will present the results obtained with low doses of gpASIT+TM subcutaneously administered alone or in combination with bacterial HSP70 (DnaK) in patients with seasonal allergic rhinitis (Phase IIa study, reference BTT-gpASIT006).
Session: Oral Abstract Session 12, Novel Vaccines for AIT
Session date and time: Sunday, 8 June 2014, 15:30-17:00
Abstract number: 66
Abstract title: Immunogenicity evaluation of subcutaneous administration of peptide hydrolysate from Lolium perenne (gpASIT+TM) in combination with bacterial HSP70 (DnaK) in patients with seasonal allergic rhinitis.
On Monday June 9th, Dr. G. Zadoyan from the team of Pr. Dr. R. Mösges (University of Köln) will present the results obtained in the Phase IIa-dose escalation study performed with gpASIT+TM alone (reference BTT-gpASIT007).
Session: Poster Discussion Session 11, Novel protocol routes and vaccines
Session date and time: Monday, 9 June 2014 (Poster Group II-Red), 15:45-17:15
Abstract number: 334
Abstract title: Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to hay fever patients – a phase IIa dose-escalation study.
gpASIT+TM is based on highly purified grass pollen allergen fragments obtained from natural sources. The use of allergen fragments reduces the risk of allergic reactions by approximately 100-fold; the very high degree of purity of the fragments results in a product with a superior safety profile. The use of natural sources of allergens results in a product including a very broad panel of epitopes allowing efficient and short course treatment.